2 462

Cited 39 times in

An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK)

DC Field Value Language
dc.contributor.author강원준-
dc.date.accessioned2015-06-10T13:05:59Z-
dc.date.available2015-06-10T13:05:59Z-
dc.date.issued2006-
dc.identifier.issn0969-8051-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/111006-
dc.description.abstractRadiolabeled αvβ3-integrin antagonists are increasingly investigated as a means of imaging angiogenesis. Several methods of labeling αvβ3-integrin binding peptide with 18F have been reported recently. In the present study, we devised a straightforward means for labeling Arg–Gly–Asp (RGD) peptide with 18F via hydrazone formation between c(RGDyK)-hydrazinonicotinic acid (HYNIC) (3) and 4-[18F]-fluorobenzaldehyde ([18F]4). The resulting reaction mixture was purified by HPLC to give 4′-[18F]-fluorobenzylidenehydrazone-6-nicotinamide-c(RGDyK) ([18F]5). The conjugation efficiency of 3 and 4 to form [18F]5 was 95.2%, and the radiochemical purity of [18F]5 after purification was >99%. The specific activity of [18F]5 estimated by radio-HPLC was 20.5 GBq/μmol (end of synthesis). Competitive binding assay of c(RGDyK) (1) and 5 was performed using [125I]iodo-c(RGDyK) as a radioligand, and Ki values were found to be 2.8 and 21.7 nM, respectively. For the biodistribution study, the angiogenic mouse model was established by inducing unilateral ischemia on the left hindlimbs of ICR mice after femoral artery ablation. Seven days after inducing ischemia, [18F]5 was administered to the mice through the tail vein. Ischemic muscle uptake of [18F]5 was significantly higher than that of normal muscle (P<.01). Specific uptake was confirmed by coinjection of 1 with [18F]5. Here, we successfully labeled RGD peptide with 18F via hydrazone formation between 3 and 4, resulting to [18F]5. [18F]5 was found to have high affinity for αvβ3-integrin and to accumulate specifically in ischemic hindlimb muscle of mice. We suggest that 18F labeling via formation of hydrazone between HYNIC peptide and [18F]4 is a useful method for labeling c(RGDyK), which can be applied for imaging angiogenesis.-
dc.description.statementOfResponsibilityopen-
dc.format.extent677~683-
dc.relation.isPartOfNUCLEAR MEDICINE AND BIOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHFluorine Radioisotopes/chemistry-
dc.subject.MESHFluorine Radioisotopes/pharmacokinetics-
dc.subject.MESHHydrazines/chemistry-
dc.subject.MESHHydrazines/pharmacokinetics-
dc.subject.MESHHydrazones/chemistry-
dc.subject.MESHHydrazones/pharmacokinetics-
dc.subject.MESHIntegrin alphaVbeta3/chemistry-
dc.subject.MESHIntegrin alphaVbeta3/metabolism*-
dc.subject.MESHIschemia/diagnostic imaging*-
dc.subject.MESHIschemia/metabolism*-
dc.subject.MESHIsotope Labeling/methods-
dc.subject.MESHMetabolic Clearance Rate-
dc.subject.MESHMice-
dc.subject.MESHMuscle, Skeletal/blood supply-
dc.subject.MESHMuscle, Skeletal/diagnostic imaging*-
dc.subject.MESHMuscle, Skeletal/metabolism*-
dc.subject.MESHNicotinic Acids/chemistry-
dc.subject.MESHNicotinic Acids/pharmacokinetics-
dc.subject.MESHOligopeptides/chemistry-
dc.subject.MESHOligopeptides/pharmacokinetics*-
dc.subject.MESHOrgan Specificity-
dc.subject.MESHRadionuclide Imaging-
dc.subject.MESHRadiopharmaceuticals/chemical synthesis-
dc.subject.MESHRadiopharmaceuticals/pharmacokinetics-
dc.subject.MESHTissue Distribution-
dc.titleAn improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Nuclear Medicine (핵의학)-
dc.contributor.googleauthorYun-Sang Lee-
dc.contributor.googleauthorJae Min Jeong-
dc.contributor.googleauthorHyung Woo Kim-
dc.contributor.googleauthorYoung Soo Chang-
dc.contributor.googleauthorYoung Joo Kim-
dc.contributor.googleauthorMee Kyung Hong-
dc.contributor.googleauthorGanesha B. Rai-
dc.contributor.googleauthorDae Yoon Chi-
dc.contributor.googleauthorWon Jun Kang-
dc.contributor.googleauthorJoo Hyun Kang-
dc.contributor.googleauthorDong Soo Lee-
dc.contributor.googleauthorJune-Key Chung-
dc.contributor.googleauthorMyung Chul Lee-
dc.contributor.googleauthorYoung-Ger Suh-
dc.identifier.doi10.1016/j.nucmedbio.2006.04.004-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00062-
dc.relation.journalcodeJ02381-
dc.identifier.eissn1872-9614-
dc.identifier.pmid16843843-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0969805106000709-
dc.subject.keywordPeptide labeling-
dc.subject.keyword18F-
dc.subject.keywordαvβ3-Integrin-
dc.subject.keywordRGD peptide-
dc.subject.keywordHYNIC-
dc.subject.keyword[18F]Fluorobenzaldehyde-
dc.contributor.alternativeNameKang, Won Jun-
dc.contributor.affiliatedAuthorKang, Won Jun-
dc.rights.accessRightsnot free-
dc.citation.volume33-
dc.citation.number5-
dc.citation.startPage677-
dc.citation.endPage683-
dc.identifier.bibliographicCitationNUCLEAR MEDICINE AND BIOLOGY, Vol.33(5) : 677-683, 2006-
dc.identifier.rimsid51912-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.